(Q43788363)

English

Imatinib

scientific article published in January 2001

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

26 November 2017

Imatinib (English)

1 reference

Europe PubMed Central

26 November 2017

author name string

K Lyseng-Williamson

1

1 reference

Europe PubMed Central

26 November 2017

B Jarvis

2

1 reference

Europe PubMed Central

26 November 2017

publication date

1 January 2001

1 reference

Europe PubMed Central

26 November 2017

1 reference

Europe PubMed Central

26 November 2017

61

1 reference

Europe PubMed Central

26 November 2017

12

1 reference

Europe PubMed Central

26 November 2017

1765-74; discussion 1775-6

1 reference

Europe PubMed Central

26 November 2017

https://scigraph.springernature.com/pub.10.2165/00003495-200161120-00007

0 references

In vivo eradication of human BCR/ABL-positive leukemia cells with an ABL kinase inhibitor

1 reference

https://pubmed.ncbi.nlm.nih.gov/11693465

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor.

1 reference

https://pubmed.ncbi.nlm.nih.gov/11693465

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance.

1 reference

https://pubmed.ncbi.nlm.nih.gov/11693465

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor

1 reference

https://pubmed.ncbi.nlm.nih.gov/11693465

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The tyrosine kinase inhibitor STI571, like interferon-alpha, preferentially reduces the capacity for amplification of granulocyte-macrophage progenitors from patients with chronic myeloid leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/11693465

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Structural mechanism for STI-571 inhibition of abelson tyrosine kinase

1 reference

https://pubmed.ncbi.nlm.nih.gov/11693465

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Growth inhibition and modulation of kinase pathways of small cell lung cancer cell lines by the novel tyrosine kinase inhibitor STI 571

1 reference

https://pubmed.ncbi.nlm.nih.gov/11693465

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Chronic myeloid leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/11693465

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Intracranial inhibition of platelet-derived growth factor-mediated glioblastoma cell growth by an orally active kinase inhibitor of the 2-phenylaminopyrimidine class.

1 reference

https://pubmed.ncbi.nlm.nih.gov/11693465

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

ARG tyrosine kinase activity is inhibited by STI571.

1 reference

https://pubmed.ncbi.nlm.nih.gov/11693465

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The selective tyrosine kinase inhibitor STI571 inhibits small cell lung cancer growth

1 reference

https://pubmed.ncbi.nlm.nih.gov/11693465

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/11693465

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Selective inhibition of cell proliferation and BCR-ABL phosphorylation in acute lymphoblastic leukemia cells expressing Mr 190,000 BCR-ABL protein by a tyrosine kinase inhibitor (CGP-57148).

1 reference

https://pubmed.ncbi.nlm.nih.gov/11693465

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Chronic myelogenous leukemia.

1 reference

https://pubmed.ncbi.nlm.nih.gov/11693465

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome

1 reference

https://pubmed.ncbi.nlm.nih.gov/11693465

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/11693465

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The dermatofibrosarcoma protuberans-associated collagen type Ialpha1/platelet-derived growth factor (PDGF) B-chain fusion gene generates a transforming protein that is processed to functional PDGF-BB.

1 reference

https://pubmed.ncbi.nlm.nih.gov/11693465

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Inhibition of the ABL kinase activity blocks the proliferation of BCR/ABL+ leukemic cells and induces apoptosis.

1 reference

https://pubmed.ncbi.nlm.nih.gov/11693465

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

In vitro cytotoxic effects of a tyrosine kinase inhibitor STI571 in combination with commonly used antileukemic agents

1 reference

https://pubmed.ncbi.nlm.nih.gov/11693465

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteins

1 reference

https://pubmed.ncbi.nlm.nih.gov/11693465

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative.

1 reference

https://pubmed.ncbi.nlm.nih.gov/11693465

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification

1 reference

https://pubmed.ncbi.nlm.nih.gov/11693465

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Synergistic activity of the new ABL-specific tyrosine kinase inhibitor STI571 and chemotherapeutic drugs on BCR-ABL-positive chronic myelogenous leukemia cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/11693465

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Growth-inhibitory effect of STI571 on cells transformed by the COL1A1/PDGFB rearrangement.

1 reference

https://pubmed.ncbi.nlm.nih.gov/11693465

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

CGP57148B (STI-571) induces differentiation and apoptosis and sensitizes Bcr-Abl-positive human leukemia cells to apoptosis due to antileukemic drugs

1 reference

https://pubmed.ncbi.nlm.nih.gov/11693465

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors

1 reference

https://pubmed.ncbi.nlm.nih.gov/11693465

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy of STI571, an abl tyrosine kinase inhibitor, in conjunction with other antileukemic agents against bcr-abl-positive cells.

1 reference

https://pubmed.ncbi.nlm.nih.gov/11693465

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/11693465

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

TEL/PDGFbetaR induces hematologic malignancies in mice that respond to a specific tyrosine kinase inhibitor

1 reference

https://pubmed.ncbi.nlm.nih.gov/11693465

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Tyrosine kinase inhibitor STI571 potentiates the pharmacologic activity of retinoic acid in acute promyelocytic leukemia cells: effects on the degradation of RARalpha and PML-RARalpha

1 reference

https://pubmed.ncbi.nlm.nih.gov/11693465

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.2165/00003495-200161120-00007

1 reference

Europe PubMed Central

26 November 2017

Dimensions Publication ID

0 references

1 reference

Europe PubMed Central

26 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43788363&oldid=2103340822"